Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

Olga Blau, MD PhD, Franziska Behrenbeck, Nikola Suckert, Lars R. Fransecky, MD, Claudia D. Baldus, MD, Renate Arnold, MD PhD, Antonio Pezzutto, MD PhD, Bernd Dörken, MD PhD, Igor Wolfgang Blau, MD PhD

Blood (2016) 128 (22): 2891.

https://doi.org/10.1182/blood.V128.22.2891.2891

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP and IEWP) of the EBMT

Rafal Machowicz, MD MSc, Felipe Suarez, MD PhD, Wieslaw W Jedrzejczak, MD PhD, Dirk-Jan Eikema, Liesbeth C de Wreede, PhD, Henric-Jan Blok, Cecilia Isaksson, MD, Hermann Einsele, MD, Xavier Poiré, MD, Manos Nikolousis, MD PhD, Jan-Erik Johansson, MD PhD, Guido Kobbe, MD, Marco Zecca, MD, Renate Arnold, MD PhD, Jose L. Diez-Martin, MD PhD, Stefan Schönland, MD, Arjan C Lankester, MD PhD, Andrew Gennery, MD, Nicolaus Kroeger, MD Prof

Blood (2016) 128 (22): 3490.

https://doi.org/10.1182/blood.V128.22.3490.3490

Published: 2016

Journal Articles

Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis

Philipp Hemmati, MD, Christin Vogelsänger, Theis Terwey, MD, Christian Jehn, MD, Lam G. Vuong, MD PhD, Igor Wolfgang Blau, MD, Olaf Penack, MD, Bernd Dörken, Renate Arnold, MD PhD

Blood (2016) 128 (22): 4556.

https://doi.org/10.1182/blood.V128.22.4556.4556

Published: 2016

Journal Articles

Matched Unrelated Donor Allogeneic Stem Cell Transplantation in High Risk Acute Lymphoblastic Leukemia (ALL) After a Preparative Regimen of Hyperfractionated Total Body Irradiation and High-Dose Etoposide – A Feasibility Study within the German Multicenter Study Group for Adult ALL.

Dietrich W. Beelen, MD, PhD, Renate Arnold, MD, PhD, Theis Terwey, MD, Nina K. Steckel, MD, Nicola Goekbuget, MD, Hoelzer Dieter, MD, PhD

Blood (2009) 114 (22): 3389.

https://doi.org/10.1182/blood.V114.22.3389.3389

Published: 2009

Journal Articles

Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy

Philipp D. le Coutre, Philipp Hemmati, Stefan Neuburger, Theis Terwey, Gero Massenkeil, Peter Daniel, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4419.

https://doi.org/10.1182/blood.V112.11.4419.4419

Published: 2008

Journal Articles

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Stefan Neuburger, MD, Philipp Hemmati, MD, Theis Terwey, MD, Gero Massenkeil, MD, Bernd Dörken, MD, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 4297.

https://doi.org/10.1182/blood.V112.11.4297.4297

Published: 2008

Journal Articles

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Philipp Hemmati, Theis Terwey, Gero Massenkeil, MD, Philipp D. le Coutre, MD, Stefan Neuburger, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3276.

https://doi.org/10.1182/blood.V112.11.3276.3276

Published: 2008

Journal Articles

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

Philipp Hemmati, Gero Massenkeil, MD, Theis Terwey, Stefan Neuburger, Philipp D. le Coutre, MD, Lam G Vuong, Bernd Dörken, Renate Arnold, MD, PhD

Blood (2008) 112 (11): 3278.

https://doi.org/10.1182/blood.V112.11.3278.3278

Published: 2008

Journal Articles

General Condition and Early Complications Have in Addition to Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15–55 years).

Blood (2008) 112 (11): 1927.

https://doi.org/10.1182/blood.V112.11.1927.1927

Published: 2008

Journal Articles

Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).

Blood (2008) 112 (11): 1971.

https://doi.org/10.1182/blood.V112.11.1971.1971

Published: 2008

Journal Articles

Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

Nicola Gökbuget, MD, Renate Arnold, MD, PhD, Angelika Böhme, MD, PhD, Rainer Fietkau, MD, PhD, Mathias Freund, MD, PhD, Arnold Ganser, MD, PhD, Michael Kneba, MD, PhD, Thomas Lipp, MD, Wolf-Dieter Ludwig, MD, PhD, Georg Maschmeyer, MD, PhD, Dorle Messerer, Harald Rieder, MD, PhD, Eckard Thiel, MD, PhD, Dieter Hoelzer, MD, PhD

Blood (2007) 110 (11): 12.

https://doi.org/10.1182/blood.V110.11.12.12

Published: 2007

NARROW

DNMT3A Mutations in AML Patients: Prognostic Impact and Comparative Analysis of Mutations Burden in Diagnostic Samples, after Standard Therapy, and after Allogeneic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in Hemophagocytic Lymphohistiocytosis (HLH) in Adults: A Retrospective Study of the Chronic Malignancies and Inborn Errors Working Parties (CMWP and IEWP) of the EBMT

Efficacy of Adoptive Immunotherapy By Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation from Related an Unrelated Donors: A Single Center Retrospective Analysis

Matched Unrelated Donor Allogeneic Stem Cell Transplantation in High Risk Acute Lymphoblastic Leukemia (ALL) After a Preparative Regimen of Hyperfractionated Total Body Irradiation and High-Dose Etoposide – A Feasibility Study within the German Multicenter Study Group for Adult ALL.

Allogeneic Stem Cell Transplantation (SCT) in Advanced Chronic Myeloid Leukemia (CML) Patients after Tyrosine Kinase Inhibitor (TKI) Therapy

Secondary Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Combined with Leukemic Risk Factors Predict Outcome of AML Patients after Allogeneic Stem Cell Transplantation Following Reduced Intensity Conditioning (RIC).

Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation in AML Patients with An Intermediate Risk Karyotype: No Difference in Outcome as Compared to Standard Myeloablative Conditioning (MAC).

General Condition and Early Complications Have in Addition to Disease- Specific Factors a Significant Impact on Outcome - Prognostic Factors Revisited in 1657 Adult ALL Patients (15–55 years).

Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).

Improved Outcome in High Risk and Very High Risk ALL by Risk Adapted SCT and in Standard Risk ALL by Intensive Chemotherapy in 713 Adult ALL Patients Treated According to the Prospective GMALL Study 07/2003.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only